Skip to main content

Articles

Page 2 of 33

  1. Blood-based biomarkers for dementia are gaining attention due to their non-invasive nature and feasibility in regular healthcare settings. Here, we explored the associations between 249 metabolites with all-ca...

    Authors: Yi-Xuan Qiang, Jia You, Xiao-Yu He, Yu Guo, Yue-Ting Deng, Pei-Yang Gao, Xin-Rui Wu, Jian-Feng Feng, Wei Cheng and Jin-Tai Yu
    Citation: Alzheimer's Research & Therapy 2024 16:16
  2. Alzheimer’s disease (AD) is a degenerative neurological disorder. Recent studies have indicated that histone deacetylases (HDACs) are among the most prominent epigenetic therapy targets and that HDAC inhibitor...

    Authors: Miaomiao Zhang, Wanyao Wang, Qun Ye, Yun Fu, Xuemin Li, Ke Yang, Fan Gao, An Zhou, Yonghui Wei, Shuang Tian, Shen Li, Fengjiang Wei, Wentao Shi and Wei-Dong Li
    Citation: Alzheimer's Research & Therapy 2024 16:15
  3. Uncovering the functional relevance underlying verbal declarative memory (VDM) genome-wide association study (GWAS) results may facilitate the development of interventions to reduce age-related memory decline ...

    Authors: Hao Mei, Jeannette Simino, Lianna Li, Fan Jiang, Joshua C. Bis, Gail Davies, W David Hill, Charley Xia, Vilmundur Gudnason, Qiong Yang, Jari Lahti, Jennifer A. Smith, Mirna Kirin, Philip De Jager, Nicola J. Armstrong, Mohsen Ghanbari…
    Citation: Alzheimer's Research & Therapy 2024 16:14
  4. Amyloid-β42 (Aβ42) aggregation consists of a complex chain of nucleation events producing soluble oligomeric intermediates, which are considered the major neurotoxic agents in Alzheimer’s disease (AD). Cerebral l...

    Authors: Alessandra Bigi, Liliana Napolitano, Devkee M. Vadukul, Fabrizio Chiti, Cristina Cecchi, Francesco A. Aprile and Roberta Cascella
    Citation: Alzheimer's Research & Therapy 2024 16:13
  5. Cerebrospinal fluid (CSF) complement activation is a key part of neuroinflammation that occurs in the early stages of Alzheimer’s disease (AD). However, the associations of CSF complement proteins with AD path...

    Authors: Meng Li, Ya-Hui Ma, Yun Guo, Jia-Yao Liu and Lan Tan
    Citation: Alzheimer's Research & Therapy 2024 16:12
  6. Authors: Long Xie, Sandhitsu R. Das, Laura E. M. Wisse, Ranjit Ittyerah, Robin de Flores, Leslie M. Shaw, Paul A. Yushkevich and David A. Wolk
    Citation: Alzheimer's Research & Therapy 2024 16:11

    The original article was published in Alzheimer's Research & Therapy 2023 15:79

  7. The Genetic Frontotemporal Initiative Staging Group has proposed clinical criteria for the diagnosis of prodromal frontotemporal dementia (FTD), termed mild cognitive and/or behavioral and/or motor impairment ...

    Authors: Alberto Benussi, Enrico Premi, Mario Grassi, Antonella Alberici, Valentina Cantoni, Stefano Gazzina, Silvana Archetti, Roberto Gasparotti, Giorgio G. Fumagalli, Arabella Bouzigues, Lucy L. Russell, Kiran Samra, David M. Cash, Martina Bocchetta, Emily G. Todd, Rhian S. Convery…
    Citation: Alzheimer's Research & Therapy 2024 16:10
  8. Metabotropic glutamate receptor 5 (mGluR5) is involved in regulating integrative brain function and synaptic transmission. Aberrant mGluR5 signaling and relevant synaptic failure play a key role in the initial...

    Authors: Jie Wang, Yingfang He, Xing Chen, Lin Huang, Junpeng Li, Zhiwen You, Qi Huang, Shuhua Ren, Kun He, Roger Schibli, Linjing Mu, Yihui Guan, Qihao Guo, Jun Zhao and Fang Xie
    Citation: Alzheimer's Research & Therapy 2024 16:9
  9. Specific peripheral proteins have been implicated to play an important role in the development of Alzheimer’s disease (AD). However, the roles of additional novel protein biomarkers in AD etiology remains elus...

    Authors: Jingjing Zhu, Shuai Liu, Keenan A. Walker, Hua Zhong, Dalia H. Ghoneim, Zichen Zhang, Praveen Surendran, Sarah Fahle, Adam Butterworth, Md Ashad Alam, Hong-Wen Deng, Chong Wu and Lang Wu
    Citation: Alzheimer's Research & Therapy 2024 16:8
  10. APOE4 is the strongest genetic risk factor for sporadic Alzheimer’s disease (AD), whereas APOE2 confers protection. However, effects of APOE on neurodegeneration in cognitively intact individuals, and how these a...

    Authors: Emilie T. Reas, Curtis Triebswetter, Sarah J. Banks and Linda K. McEvoy
    Citation: Alzheimer's Research & Therapy 2024 16:7
  11. Repeated sessions of training and non-invasive brain stimulation have the potential to enhance cognition in patients with cognitive impairment. We hypothesized that combining cognitive training with anodal tra...

    Authors: Daria Antonenko, Anna Elisabeth Fromm, Friederike Thams, Anna Kuzmina, Malte Backhaus, Elena Knochenhauer, Shu-Chen Li, Ulrike Grittner and Agnes Flöel
    Citation: Alzheimer's Research & Therapy 2024 16:6
  12. Alzheimer’s dementia (AD) pathogenesis involves complex mechanisms, including microRNA (miRNA) dysregulation. Integrative network and machine learning analysis of miRNA can provide insights into AD pathology a...

    Authors: Sang-Won Han, Jung-Min Pyun, Paula J. Bice, David A. Bennett, Andrew J. Saykin, Sang Yun Kim, Young Ho Park and Kwangsik Nho
    Citation: Alzheimer's Research & Therapy 2024 16:5
  13. Amyloid beta (Aβ) deposits and hyperphosphorylated tau (p-tau) accumulation have been identified in the retina of Alzheimer’s disease (AD) patients and transgenic AD mice. Previous studies have shown that reti...

    Authors: Cristina Nuñez-Diaz, Emelie Andersson, Nina Schultz, Dovilė Pocevičiūtė, Oskar Hansson, K Peter R. Nilsson and Malin Wennström
    Citation: Alzheimer's Research & Therapy 2024 16:4
  14. Recently, single-nucleus RNA-seq (snRNA-seq) analyses have revealed important cellular and functional features of Alzheimer's disease (AD), a prevalent neurodegenerative disease. However, our knowledge regardi...

    Authors: Andi Liu, Brisa S. Fernandes, Citu Citu and Zhongming Zhao
    Citation: Alzheimer's Research & Therapy 2024 16:3
  15. Disease-modifying treatments for Alzheimer’s disease highlight the need for early detection of cognitive decline. However, at present, most primary care providers do not perform routine cognitive testing, in p...

    Authors: Ali Jannati, Claudio Toro-Serey, Joyce Gomes-Osman, Russell Banks, Marissa Ciesla, John Showalter, David Bates, Sean Tobyne and Alvaro Pascual-Leone
    Citation: Alzheimer's Research & Therapy 2024 16:2
  16. Apolipoprotein-E (APOE) genetic testing for Alzheimer’s disease is becoming more important as clinical trials are increasingly targeting individuals carrying APOE-ε4 alleles. Little is known about the interest...

    Authors: Lisa Waterink, Larissa A. Masselink, Sven J. van der Lee, Leonie N. C. Visser, Solange Cleutjens, Jetske van der Schaar, Argonde C. van Harten, Philip Scheltens, Sietske A. M. Sikkes, Wiesje M. van der Flier and Marissa D. Zwan
    Citation: Alzheimer's Research & Therapy 2024 16:1
  17. Disturbances in brain cholesterol homeostasis may be involved in the pathogenesis of Alzheimer’s disease (AD). Lipid-lowering medications could interfere with neurodegenerative processes in AD through choleste...

    Authors: Bojana Petek, Henrike Häbel, Hong Xu, Marta Villa-Lopez, Irena Kalar, Minh Tuan Hoang, Silvia Maioli, Joana B. Pereira, Shayan Mostafaei, Bengt Winblad, Milica Gregoric Kramberger, Maria Eriksdotter and Sara Garcia-Ptacek
    Citation: Alzheimer's Research & Therapy 2023 15:220
  18. Modifiable lifestyle behaviors account for a large proportion of dementia risk. However, the combined contributions of multidomain lifestyle patterns to cognitive aging are poorly understood, as most studies h...

    Authors: Emily W. Paolillo, Rowan Saloner, Anna VandeBunte, Shannon Lee, David A. Bennett and Kaitlin B. Casaletto
    Citation: Alzheimer's Research & Therapy 2023 15:221
  19. Clinical variants of primary progressive aphasia (PPA) are diagnosed based on characteristic patterns of language deficits, supported by corresponding neural changes on brain imaging. However, there is (i) con...

    Authors: Siddharth Ramanan, Ajay D. Halai, Lorna Garcia-Penton, Alistair G. Perry, Nikil Patel, Katie A. Peterson, Ruth U. Ingram, Ian Storey, Stefano F. Cappa, Eleonora Catricala, Karalyn Patterson, James B. Rowe, Peter Garrard and Matthew A. Lambon Ralph
    Citation: Alzheimer's Research & Therapy 2023 15:219
  20. White matter (WM) microstructural changes in the hippocampal cingulum bundle (CBH) in Alzheimer’s disease (AD) have been described in cohorts of largely European ancestry but are lacking in other populations.

    Authors: Lauren R. Hirschfeld, Rachael Deardorff, Evgeny J. Chumin, Yu-Chien Wu, Brenna C. McDonald, Sha Cao, Shannon L. Risacher, Dahyun Yi, Min Soo Byun, Jun-Young Lee, Yu Kyeong Kim, Koung Mi Kang, Chul-Ho Sohn, Kwangsik Nho, Andrew J. Saykin and Dong Young Lee
    Citation: Alzheimer's Research & Therapy 2023 15:218
  21. Neurodegeneration and structural changes in the brain due to amyloid deposition have been observed even in individuals with mild cognitive impairment (MCI). EEG measurement is considered an effective tool beca...

    Authors: Osamu Katayama, Yaakov Stern, Christian Habeck, Sangyoon Lee, Kenji Harada, Keitaro Makino, Kouki Tomida, Masanori Morikawa, Ryo Yamaguchi, Chiharu Nishijima, Yuka Misu, Kazuya Fujii, Takayuki Kodama and Hiroyuki Shimada
    Citation: Alzheimer's Research & Therapy 2023 15:217
  22. Alzheimer’s disease (AD) is characterized by cognitive dysfunction and amyloid plaques composed of the amyloid-beta peptide (Aβ). APOE is the greatest genetic risk for AD with APOE4 increasing risk up to ~ 15-fol...

    Authors: Ana C. Valencia-Olvera, Deebika Balu, Shreya Bellur, Thomas McNally, Yaseen Saleh, Don Pham, Shivesh Ghura, Jason York, Jan O. Johansson, Mary Jo LaDu and Leon Tai
    Citation: Alzheimer's Research & Therapy 2023 15:216
  23. NeuroEPO plus is a recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life due to its low sialic acid content. NeuroEPO plus prevents oxidative damage, neuroinflammation, ...

    Authors: Saily Sosa, Giosmany Bringas, Nelky Urrutia, Ana Ivis Peñalver, Danay López, Evelio González, Ana Fernández, Zenaida Milagros Hernández, Ariel Viña, Yamile Peña, Juan Felipe Batista, Carmen Valenzuela, Kalet León, Tania Crombet, Teresita Rodríguez and Leslie Pérez
    Citation: Alzheimer's Research & Therapy 2023 15:215
  24. Alzheimer’s disease (AD) and vascular dementia (VaD) are two of the commonest causes of dementia in the elderly. Of the myriad biomolecules implicated in dementia pathogenesis, sphingolipids have attracted rel...

    Authors: Xin Ying Chua, Federico Torta, Joyce R. Chong, Narayanaswamy Venketasubramanian, Saima Hilal, Markus R. Wenk, Christopher P. Chen, Thiruma V. Arumugam, Deron R. Herr and Mitchell K. P. Lai
    Citation: Alzheimer's Research & Therapy 2023 15:214
  25. Genome-wide association studies demonstrate that Alzheimer’s disease (AD) has a highly polygenic architecture, where thousands of independent genetic variants explain risk with high classification accuracy. Th...

    Authors: Thomas Lancaster, Byron Creese, Valentina Escott-Price, Ian Driver, Georgina Menzies, Zunera Khan, Anne Corbett, Clive Ballard, Julie Williams, Kevin Murphy and Hannah Chandler
    Citation: Alzheimer's Research & Therapy 2023 15:213
  26. Developing a screening method for identifying individuals at higher risk of elevated brain amyloid burden is important to reduce costs and burden to patients in clinical trials on Alzheimer’s disease or the cl...

    Authors: Noriyuki Kimura, Tomoki Aota, Yasuhiro Aso, Kenichi Yabuuchi, Kotaro Sasaki, Teruaki Masuda, Atsuko Eguchi, Yoshitaka Maeda, Ken Aoshima and Etsuro Matsubara
    Citation: Alzheimer's Research & Therapy 2023 15:212
  27. Identifying individuals with mild cognitive impairment (MCI) who are likely to progress to Alzheimer’s disease and related dementia disorders (ADRD) would facilitate the development of individualized preventio...

    Authors: Gang Li, Nicola Toschi, Viswanath Devanarayan, Richard Batrla, Tommaso Boccato, Min Cho, Matteo Ferrante, Feride Frech, James E. Galvin, David Henley, Soeren Mattke, Susan De Santi and Harald Hampel
    Citation: Alzheimer's Research & Therapy 2023 15:211
  28. Dementia is defined as a cognitive decline that affects functional status. Longitudinal ageing surveys often lack a clinical diagnosis of dementia though measure cognition and daily function over time. We used...

    Authors: Amin Gharbi-Meliani, François Husson, Henri Vandendriessche, Eleonore Bayen, Kristine Yaffe, Anne-Catherine Bachoud-Lévi and Laurent Cleret de Langavant
    Citation: Alzheimer's Research & Therapy 2023 15:209
  29. To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI).

    Authors: I. S. van Maurik, E. D. Bakker, A. A. J. M. van Unnik, H. M. Broulikova, M. D. Zwan, E. van de Giessen, J. Berkhof, F. H. Bouwman, J. E. Bosmans and W. M. van der Flier
    Citation: Alzheimer's Research & Therapy 2023 15:208
  30. Previous studies demonstrated increases in diagnostic confidence and change in patient management after amyloid-PET. However, studies investigating longitudinal outcomes over an extended period of time are lim...

    Authors: Lyduine E. Collij, Gill Farrar, Marissa Zwan, Elsmarieke van de Giessen, Rik Ossenkoppele, Frederik Barkhof, Annemieke J. M. Rozemuller, Yolande A. L. Pijnenburg, Wiesje M. van der Flier and Femke Bouwman
    Citation: Alzheimer's Research & Therapy 2023 15:207
  31. High gait variability is associated with neurodegeneration and cognitive impairments and is predictive of cognitive impairment and dementia. The objective of this study was to identify cortical or subcortical ...

    Authors: Seonjeong Byun, Hyang Jun Lee, Jun Sung Kim, Euna Choi, Subin Lee, Tae Hui Kim, Jae Hyoung Kim, Ji Won Han and Ki Woong Kim
    Citation: Alzheimer's Research & Therapy 2023 15:206
  32. Cognitive complaints are often regarded as an early sign of Alzheimer’s disease (AD) but may also occur in several other conditions and contexts. This study examines the correlates of cognitive complaint traje...

    Authors: Federica Cacciamani, Ariane Bercu, Vincent Bouteloup, Leslie Grasset, Vincent Planche, Geneviève Chêne and Carole Dufouil
    Citation: Alzheimer's Research & Therapy 2023 15:205
  33. There are increasing reports on the cognitive and emotional benefits of positive reminiscence therapy in older people. The objective of this study is to assess the differential improvement of the quality of li...

    Authors: Alba Villasán Rueda, Antonio Sánchez Cabaco, Manuel Alejandro Mejía-Ramírez, Rosa Marina Afonso and Eduardo Castillo-Riedel
    Citation: Alzheimer's Research & Therapy 2023 15:204
  34. Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an area of active treatmen...

    Authors: Marina Ritchie, Daniel L. Gillen and Joshua D. Grill
    Citation: Alzheimer's Research & Therapy 2023 15:203
  35. Identification of patients with idiopathic normal pressure hydrocephalus (iNPH) in a collective with suspected neurodegenerative disease is essential. This study aimed to determine the metabolic spatial covari...

    Authors: Alexander Rau, Nils Schröter, Ganna Blazhenets, Christoph Maurer, Horst Urbach, Philipp T. Meyer and Lars Frings
    Citation: Alzheimer's Research & Therapy 2023 15:202
  36. Progression of Alzheimer’s disease leads to synapse loss, neural network dysfunction and cognitive failure. Accumulation of protein aggregates and brain immune activation have triggering roles in synaptic fail...

    Authors: Austin Stoner, Li Fu, LaShae Nicholson, Chao Zheng, Takuya Toyonaga, Joshua Spurrier, Will Laird, Zhengxin Cai and Stephen M. Strittmatter
    Citation: Alzheimer's Research & Therapy 2023 15:201
  37. Health-related quality of life (HR-QoL) is an important outcome for patients and crucial for demonstrating the value of new treatments. Health utility estimates in subjective cognitive decline (SCD) and mild c...

    Authors: Sandar Aye, Vincent Bouteloup, Ashley Tate, Anders Wimo, Ron Handels, Delphine Jean, Bengt Winblad and Linus Jönsson
    Citation: Alzheimer's Research & Therapy 2023 15:200
  38. Understanding the pathological characteristics of various mild cognitive impairment (MCI) subtypes is crucial for the differential diagnosis of dementia. The purpose of this study was to feature divergent symp...

    Authors: Chao Du, Mingxi Dang, Kewei Chen, Yaojing Chen and Zhanjun Zhang
    Citation: Alzheimer's Research & Therapy 2023 15:199
  39. Subjective cognitive complaints (SCC) have been mostly studied in the context of Alzheimer’s disease in memory clinic settings. The potential of combining SCC with genetic information and blood biomarkers of ...

    Authors: Laura Perna, Hannah Stocker, Lena Burow, Léon Beyer, Kira Trares, Carolin Kurz, Selim Gürsel, Bernd Holleczek, Maia Tatò, Konrad Beyreuther, Ute Mons, Klaus Gerwert, Robert Perneczky, Ben Schöttker and Hermann Brenner
    Citation: Alzheimer's Research & Therapy 2023 15:198
  40. Cholesterol plays important roles in β-amyloid (Aβ) metabolism and atherosclerosis. However, the relationships of plasma cholesterol levels with Aβ and cerebral small vessel disease (CSVD) burdens are not full...

    Authors: Sung Hoon Kang, Heejin Yoo, Bo Kyoung Cheon, Yu Hyun Park, Soo-Jong Kim, Hongki Ham, Hyemin Jang, Hee Jin Kim, Kyungmi Oh, Seong-Beom Koh, Duk L. Na, Jun Pyo Kim and Sang Won Seo
    Citation: Alzheimer's Research & Therapy 2023 15:197
  41. Genomic study of cognition decline while considering baseline cognition and lifestyle behaviors is scarce. We aimed to evaluate the impact of a polygenic score for general cognition on cognition decline rate, ...

    Authors: Tingting Liu, Changwei Li, Ruiyuan Zhang, Eugenia Flores Millender, Hongyu Miao, Michael Ormsbee, Jinzhen Guo, Adrianna Westbrook, Yang Pan, Jing Wang and Tanika N. Kelly
    Citation: Alzheimer's Research & Therapy 2023 15:196
  42. The Alzheimer’s disease (AD) risk gene ABCA7 has suggested functions in lipid metabolism and the immune system. Rare premature termination codon (PTC) mutations and an expansion of a variable number of tandem rep...

    Authors: Lena Duchateau, Fahri Küҫükali, Arne De Roeck, Mandy M. J. Wittens, Joke Temmerman, Ilse Weets, Maarten Timmers, Sebastiaan Engelborghs, Maria Bjerke and Kristel Sleegers
    Citation: Alzheimer's Research & Therapy 2023 15:195
  43. Inflammation plays a key role in the development of dementia, but its link to early biomarkers, particularly those in plasma or neuroimaging, remains elusive. This study aimed to investigate the association be...

    Authors: Amber Yaqub, Samer R. Khan, Meike W. Vernooij, P. Martin van Hagen, Robin P. Peeters, M. Arfan Ikram, Layal Chaker and Virgil A. S. H. Dalm
    Citation: Alzheimer's Research & Therapy 2023 15:194
  44. The pathological process of Alzheimer’s disease (AD) typically takes decades from onset to clinical symptoms. Early brain changes in AD include MRI-measurable features such as altered functional connectivity (...

    Authors: Yujian Diao, Bernard Lanz and Ileana Ozana Jelescu
    Citation: Alzheimer's Research & Therapy 2023 15:193
  45. We have proposed that cognitive resilience (CR) counteracts brain damage from Alzheimer’s disease (AD) or AD-related dementias such that older individuals who harbor neurodegenerative disease burden sufficient...

    Authors: Thanaphong Phongpreecha, Dana Godrich, Eloise Berson, Camilo Espinosa, Yeasul Kim, Brenna Cholerton, Alan L. Chang, Samson Mataraso, Syed A. Bukhari, Amalia Perna, Koya Yakabi, Kathleen S. Montine, Kathleen L. Poston, Elizabeth Mormino, Lon White, Gary Beecham…
    Citation: Alzheimer's Research & Therapy 2023 15:192
  46. Alzheimer’s disease is a prevalent disease with a heavy global burden. Proteomics is the systematic study of proteins and peptides to provide comprehensive descriptions. Aiming to obtain a more accurate and co...

    Authors: Yuye Wang, Yu Sun, Yu Wang, Shuhong Jia, Yanan Qiao, Zhi Zhou, Wen Shao, Xiangfei Zhang, Jing Guo, Bin Zhang, Xiaoqian Niu, Yi Wang and Dantao Peng
    Citation: Alzheimer's Research & Therapy 2023 15:191
  47. There is a tremendous need for identifying reliable blood-based biomarkers for Alzheimer’s disease (AD) that are tied to the biological ATN (amyloid, tau and neurodegeneration) framework as well as clinical as...

    Authors: Zhengshi Yang, Karthik Sreenivasan, Erin N. Toledano Strom, Amanda M. Leisgang Osse, Lorenzo Gabriel Pasia, Celica Glenn Cosme, Maya Rae N. Mugosa, Emma Léa Chevalier, Aaron Ritter, Justin B. Miller, Dietmar Cordes, Jeffrey L. Cummings and Jefferson W. Kinney
    Citation: Alzheimer's Research & Therapy 2023 15:190
  48. The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer’s disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, pote...

    Authors: Ilse Bader, Ilona Bader, Isadora Lopes Alves, David Vállez García, Bruno Vellas, Bruno Dubois, Mercè Boada, Marta Marquié, Daniele Altomare, Philip Scheltens, Rik Vandenberghe, Bernard Hanseeuw, Michael Schöll, Giovanni B. Frisoni, Frank Jessen, Agneta Nordberg…
    Citation: Alzheimer's Research & Therapy 2023 15:189